NCT01259323View on ClinicalTrials.gov

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Dermatitis
Interventions
BIOLOGICAL

REGN668

Dose 1: REGN668 or placebo

BIOLOGICAL

REGN668

Dose 2: REGN668 or placebo

BIOLOGICAL

REGN668

Dose 3: REGN668 or placebo

Trial Locations (10)

Unknown

Los Angeles

Riverside

Miami

Chicago

Troy

New York

Rochester

Portland

Philadelphia

Dallas

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01259323 - Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter